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ABSTRACT 
 
HepaRG progenitor cells are capable to differentiate into hepatocyte-like cells expressing a large set of 
liver specific functions. These cells, however, express little amounts of an important cytochrome 
P450, the CYP2E1, which limits their use for toxicological studies of drugs metabolized by this 
pathway. We aimed at establishing efficient protocols of transfection in order to increase CYP2E1 
expression in HepaRG cells. Transfection protocols of the GFP reporter gene were evaluated using 
electroporation and cationic lipids belonging to the lipophosphonates, lipophosphoramidates and lipids 
derived from glycine betaine. Following optimization of the charge ratios, plasmid DNA amounts and 
formulations with neutral co-lipids, the lipophosphoramidate compounds KLN47 and BSV10 allowed 
expression of the GFP in ~50% of adherent progenitor HepaRG cells while electroporation targeted 
GFP expression in ~85% of both progenitor and differentiated cells in suspension. Then, transient 
enforced expression of active CYP2E1 was achieved in progenitors and/or differentiated HepaRG 
cells using the electroporation and the lipophosphoramidate compound BSV10. Importantly, in 
electroporated cells, CYP2E1 expression level was correlated with a significant increase in CYP2E1-
specific enzymatic activity, which opens new perspectives for this CYP-dependent drug metabolism 
and toxicity studies using HepaRG cells. 
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Differentiated hepatocytes perform many complex metabolic processes including synthesis and 
secretion of plasma proteins, synthesis and storage of glycogen and detoxication of endogenous toxins 
and xenobiotics. To study the process of differentiation and to characterize the enzymatic activities in 
the hepatocytes two main categories of in vitro models have been developed over the past 20 years: the 
primary cultures of normal hepatocytes and the hepatoma cell lines. Human hepatocytes can be plated 
in culture conditions maintaining cell survival and expression of liver specific functions for several 
days to weeks [1]. Although, these models have proven to be relevant for studying some aspects of the 
liver biology such as induction of drug metabolism enzymes (DMEs) by xenobiotics, large variations 
in functional activities especially for cytochrome P450 enzymes (CYP) have been observed in human 
hepatocytes isolated from different donors [1]. In addition, the relative shortage and unpredictable 
availability of human biopsies along with the limited growth activity and lifespan of hepatocytes in 
primary culture limit the use of these models. 
Alternatively, hepatoma cell lines have been established from differentiated hepatocellular 
carcinomas that retain various expression levels of liver specific proteins. These cells contain low 
CYP activities [2], which limits their use for studying liver metabolism and toxicity of xenobiotics. 
Enforced expression of CYPs has been obtained in hepatoma cells by transient or stable transfection of 
expression vectors encoding the CYPs themselves or liver-specific transcription factor such as C/EBP 
alpha [3]. Although these transfected cells are relevant models to identify DMEs involved in 
metabolism of new drugs, high expression levels of a limited number of transfected CYPs occur in 
absence of the full panel of DMEs from phases I, II and III required for the complete metabolism of 
xenobiotics as observed in the liver.  
The human hepatoma cell line HepaRG derived from a hepatocellular carcinoma [4] circumvents 
these drawbacks by expressing most of the liver specific functions including high levels of the major 
CYPs such as CYP3A4 and CYP1A2 [5, 6]. Progenitors HepaRG cells that differentiate into 
hepatocyte-like cells also represent a unique in vitro cell system to investigate the process of 
differentiation from hepatic progenitor cells towards hepatocyte-like cells [7] as well as the 
phenomenon of transdifferentiation from hepatocyte to biliary phenotypes or vice versa [7]. In 
addition, this hepatoma cell line provides a valuable in vitro model for investigating replication of the 
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Hepatitis B Virus [4], drug metabolism [5, 6, 8] as well as studies of genotoxic compounds [9]. 
However, the relatively low levels of the CYP2E1 enzyme in HepaRG cells [5, 6] limit their use for 
analyzing biotransformation of xenobiotics specifically metabolized by this DME. The CYP2E1 plays 
a major role in the metabolism of many xenobiotics in all humans [10]. Thus, expression of higher 
levels of CYP2E1, achieved by transfection in differentiated HepaRG cells, would be particularly 
useful to complete the pathways of biotransformation in these cells.  
It is generally accepted that hepatic cells, especially primary hepatocytes, are difficult to transfect 
[11]. Liposome mediated transient transfection using the most recent cationic lipids allowed gene 
delivery in 10 to 30% of rodent and human hepatocytes in primary culture. These protocols were 
useful to study regulatory gene sequences [11] but remained of limited help to study the effect(s) of 
enforced expression of gene of interest in whole cell populations because of the relatively low rate of 
transfection. 
Because of the raising interest in HepaRG cells for drug metabolism studies and for analyzing the 
process of differentiation from hepatic progenitors towards hepatocytes, optimization of HepaRG cell 
transfection has become a pertinent task. The aim of this work was first to establish efficient protocols 
of transfection of both progenitor and differentiated HepaRG cells, then to achieve enforced 
expression of CYP2E1 protein.  
The HepaRG cells are available from Dr. Guillouzo (christiane.guillouzo@univ-rennes1.fr) for 
academic laboratories and from Dr. Chesné (christophe.chesne@biopredic.com) for industrial 
laboratories. Progenitor HepaRG cells were cultured as previously described [4, 5, 7]. For full 
expression of liver specific genes in hepatocyte-like cells, the culture medium was supplemented with 
2% DMSO for 2 more weeks [5].  
A panel of commercial transfection reagents (Supplemental data S1) and the pEGFP-C3 
(Clontech, Saint Germain en Laye, France) expression vector encoding the Green Fluorescent Protein 
(GFP) were used to transfect HepaRG cells. GFP positive cells were detected 48 h after transfection 
using the FC500 cytometer (Beckman Coulter, France). The mean of fluorescence (Geo mean) was 
determined for the GFP positive cell population. To determine background fluorescence, HepaRG 
cells were transfected with the non coding pC3 plasmid (pEGFP-C3 lacking the GFP cDNA). Cell 
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viability was assessed using the Side Scatter (SSC) versus Forward Scatter (FSC) dot plot. Previous 
experiments showed a clear decrease in size (FSC) and increase in structure (SSC) in HepaRG cells 
undergoing necrosis or apoptosis compared to viable cells. GFP positive cells were visualized with a 
Zeiss fluorescent microscope and the AxioVision LE Rel. 4.3 software.  
In progenitor HepaRG cells, Lipofectamine 2000® was the most potent transfection reagent 
with an efficiency reaching 25% of GFP positive cells but with a strong toxicity. Other reagents 
allowed GFP expression in only 10 to 15% of cells. In differentiated hepatocyte-like cells, transfection 
rates were even lower (1 to 14%) than in progenitor cells (Supplemental data S1). 
We next evaluated the lipophosphonates GLB43 and EG316 and lipophosphoramidates 
KLN25, KLN47 and BSV10 (Figure 1) [12, 13]. We also evaluated the MM18 compound belonging 
to a family of glycine betaine lipids efficient for transfection in mouse hepatocytes [14]. The 
lipophosphonates GLB43 and EG316, lipophosphoramidates KLN47 and BSV10 have been 
previously reported [12]. For the KLN25 and the glycine betaine MM18 [13], the synthesis are 
detailed in Supplemental data S2 and S3. All lipids are presented in Supplemental data S4 and the 
preparation of liposomes is described in Supplemental data S5. Transfections with the 
lipophosphonates, lipophosphoramidates and the MM18 produced by the IBiSA plateform 
“SynNanoVect” from Biogenouest® (France) were performed using 105 cells/well (in 24-multiwells) 
plated 24 h prior transfection. Liposome suspensions (10 mg of lipids/mL) were sonicated using an 
ultrasound water bath sonicator for 5 minutes. Liposomes and plasmids (0.5µg) were diluted in 100 µL 
OptiMEM medium (Gibco) prior mixing DNA plasmid dilution with liposome suspension. The 
resulting lipoplex solutions were vortexed for 30 seconds, incubated at room temperature for 30 
minutes, added dropwise to the culture medium of HepaRG cells deprived in antibiotics and incubated 
for 4 hours with cells prior culture medium renewal.  
A broad range of charge ratios from 0.5 to 16 was tested with 0.8 µg of DNA plasmid (Figure 
1). Different liposomal compositions were also studied including either the cationic lipid alone or 
associated with the neutral co-lipids DOPE or cholesterol, known to promote fusion between the 
lipoplexe and cellular membranes and to increase lipoplexe stability, respectively. The KLN47 was 
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used alone since we previously showed that its association with DOPE and cholesterol strongly 
reduced plasmid DNA delivery. 
For the EG316, GLB43 and KLN25 liposomes (Figure 1A, B and C), the highest transfection 
efficiencies in progenitor HepaRG cells were 16 ± 3, 14 ± 1 and 7 ± 1%, respectively, at the optimal 
charge ratio of 2. The cell viability decreased with high charge ratio. With BSV10 lipid (Figure 1D), 
the percentage of GFP positive cells increased proportionally to the charge ratio up to ~20% at the 
ratios 8 and 16 but was associated with low cell viabilities. MM18 lipid was the less efficient 
compound (~5% of GFP cells) with reduced cell viability at high charge ratios (Figure 1E). The 
KLN47 compound allowed the highest gene transfer in HepaRG cells with efficiencies up to 45% for 
the charge ratio of 4 with cell viability down to ~60% of control culture (Figure 1F).  
Combining lipids EG316, GLB43, KLN25, BSV10 to the co-lipid DOPE significantly 
improved transfection efficiencies of HepaRG cells (i.e. ~40% of GFP positive cells with BSV10-
DOPE, ~80% cell viability at the charge ratio of 1). MM18 liposome formulation with 15% 
cholesterol also significantly increased the transfection rate up to 20% of GFP positive cells at the 
charge ratio of 2 (Figure 1E). The benefit of using the co-lipid DOPE is probably due to its ability to 
induce an intracellular transition of the liposome/DNA complex from a lamellar to a non-lamellar 
phase, which enhances DNA release. Similar experiments were also performed with differentiated 
HepaRG cells but none of these formulations gave transfection efficiencies higher than 10% (data not 
shown) and, thus, did not improve transfection rates obtained with commercially available reagents. In 
conclusion, the KLN47 and BSV10/DOPE formulations allowed high gene delivery in proliferating 
progenitors cells (~50%) but not in quiescent differentiated HepaRG cells in agreement with the fact 
that gene transfer by liposomes depend upon cell cycle [15].  
Then, we evaluated the Microporator MP100 from LabTech France (Paris) designed to deliver 
DNA into cells in suspension [note: the device originally engineered by Digital Bio (NanoEnTek Inc., 
Korea) is now commercialized as the NeonTM electroporator from Invitrogen (Carlsbad, USA)]. 
Progenitor HepaRG cells were detached by trysinization while differentiated HepaRG cells were 
selectively detached by mild trypsination at room temperature [7]. Cells were washed twice with PBS 
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and resuspended in buffer R (107 cells/mL). For both progenitor and hepatocyte-like HepaRG cells, 24 
conditions of electroporation were tested (Supplemental data S6).  
In progenitor cells, 16 conditions gave transfection rates between 80 and 95% of GFP positive 
cells with cell viabilities ranging from 65 to 90% (Figure 2A). Other settings led to lower transfection 
efficiencies, which, however, remained above 50% of GFP positive cells with high cell viability rates. 
In hepatocyte-like cells, electroporation also allowed efficient DNA delivery and high expression 
levels of the GFP proteins since two conditions (C5 and 4) reached transfection and cell viability rates 
above 80% (Figure 2B). The other settings led to transfection efficiencies ranging from 25 to 78% 
with cell viabilities varying considerably.  
These data demonstrated that in HepaRG cells, electroporation is a more efficient technology 
for gene delivery than the cationic lipids tested. However, the transfection using the 
lipophosphoramidate compounds KLN47 and BSV10 will be useful since gene delivery is performed 
with adherent progenitor cells in contrast with the electroporation of cell suspensions. The high rate of 
transfection in differentiated HepaRG cells by electroporation confirms the notion that electroporation 
facilitates the nuclear translocation of plasmid DNA in poorly proliferating cells [16].  
We next addressed the question of the relationship between the efficiency of transfection and 
the amount of plasmid DNA. The percentage of GFP positive cells and the mean of fluorescence were 
measured according to the amounts of DNA ranging (from 10 ng to 2 µg/105 cells) using 
electroporation and the liposomes BSV10/DOPE, GLB43/DOPE and MM18/Chol (Supplemental data 
S7).  
For electroporation, the smallest amount of DNA (10 ng) led to ~20% of GFP positive cells. 
This percentage was linear up to 0.2 µg of plasmid to reach ~70% of GFP expressing cells. For 0.3 to 
0.6 µg of plasmid, the maximal efficiency was reached (~85%) while high amounts up to 2 µg of 
plasmid slightly decreased the rate of transfection. The mean of fluorescence did not correlate the 
percentage of GFP positive cells for the small amounts of DNA but increased abruptly to reach the 
highest fluorescence intensity for the amounts between 0.3 and 0.6 µg of plasmid.  
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For BSV10/DOPE, GLB43/DOPE and MM18/Chol liposomes, optimal transfection 
efficiencies were obtained for 0.4, 1 and 0.8 µg of plasmid, respectively, and the mean of fluorescence 
correlated well with the percentage of GFP positive cells. GFP expression remained very low (<5%) 
up to 0.1µg of plasmid and was not proportional to the amount of DNA while between 0.1 and 0.4 µg 
±0.2 of DNA, this percentage was linear.  
Then, we studied whether the percentages of GFP positive cells were correlated to the 
intracellular amount of plasmid. Percentages of GFP progenitor HepaRG cells, transfected with the 
pEGFPc3, were compared to the ratio of fluorescence between cells transfected with the non coding 
rhodamine-labelled and unlabeled pC3 plasmids (Supplemental data S8). Transfection by 
electroporation or with the BSV10/DOPE liposomes that allowed 80 and 50 % of GFP positive cells 
were characterized by small fluorescence ratios of 3.5 and 4.5, respectively. In contrast, the 
GLB43/DOPE and MM18/Chol liposomes, which triggered only 15 and 5% of GFP expression, 
exhibited high fluorescence ratios of 8 and 12. In situ visualization of FITC-labelled pC3 plasmid 
confirmed that cells transfected with MM18/Chol liposomes exhibited larger and more intense 
fluorescent dots than electroporated cells. These data further confirm that the improvement of 
nucleocytoplasmic transport of plasmid DNA following non viral gene transfer is a key parameter to 
achieve high gene expression [17].  
Following the optimization of the transfection in HepaRG cells, we next assayed the transient 
ectopic expression of the CYP2E1 (Figure 3). The human CYP2E1 cDNA (obtained from Dr. De 
Waziers, INSERM U775, Université Paris Descartes, France) was amplified by PCR using the primers 
ATGTCTGCCCTCGGAGTCACC (foward) and TCATGAGCGGGGAATGACACA (reverse) and 
inserted into the pcDNA3.1/V5-His-Topo. Both progenitor and differentiated hepatocyte-like HepaRG 
cells were transfected with the pEGFPc3 or the human CYP2E1 encoding vector using electroporation 
(Figure 3A) and the lipids BSV10 and KLN47 (Figure 3C). For immunoblotting of the GFP (antibody: 
T-19, sc5384, Santa Cruz Biotechnology), the CYP3A4 (antibody: AB1254, Chemicon), the CYP2E1 
(antibody: Oxford Biomedical, USA) and the HSC70 (antibody: B-6, sc7298, Santa Cruz 
Biotechnology), cells were lysed in 50 mM Hepes pH 7.9, 150 mM NaCl, 0.1 mM EDTA, 10% 
glycerol, 0.5% Tween 20 supplemented with protease inhibitors (EDTA-free, Roche). Ten µg of total 
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proteins were resolved on 12.5% SDS-PAGE (NewPage, Invitrogen), transferred onto nitrocellulose 
membrane and immunoblotted.   
As expected, we evidenced that CYP2E1 and CYP3A4 were undetectable in progenitor cells 
while hepatocyte-like cells expressed high levels of CYP3A4 and low amounts of CYP2E1 (Figure 
3A). In contrast, progenitors and differentiated HepaRG cells electroporated with the CYP2E1 vector 
expressed much higher levels of this DME while the CYP3A4 level in hepatocyte-like cells was not 
affected by electroporation (Figure 3A). Interestingly, the highest levels of GFP and CYP2E1 were 
observed in hepatocyte-like HepaRG cells although the percentages of GFP positive cells are very 
similar in both progenitor and differentiated cells (Figure 2). This is most likely due to the high overall 
protein synthesis in differentiated versus progenitor cells. Importantly, the CYP2E1 expression level in 
transfected cells was correlated with a ~5 to 6 fold increase in the CYP2E1-specific enzymatic activity 
compared to the activity in the control cells (Figure 3B).  
We also evidenced the expression of the GFP and CYP2E1 proteins in the progenitor cells 
transfected with the BSV10/DOPE formulation and in a much lesser extend with the lipid KLN47 
(Figure 3C). However, in differentiated cells, we did not observe any significant increase in CYP2E1 
expression following transfection with these lipids while the GFP was detected at low levels (Figure 
3C).  
Together, these data demonstrated that using the electroporation, we achieved the enforced 
expression of the human CYP2E1 in differentiated HepaRG cells. This drug-metabolizing enzyme is 
of an enormous toxicological and carcinogenic importance because of its implication in the 
metabolism of a large number of chemicals such as ethanol, acetaminophen, acrylamide and many 
cancer suspected agents [10]. Thus, low expression of CYP2E1 in differentiated HepaRG cells was a 
clear limitation in their use for metabolism and toxicological studies of a wide range of molecules with 
relevance for human health. Differentiated HepaRG cells expressing high levels of the most important 
CYPs including the CYP2E1 definitely opens new perspectives for drug metabolism and toxicity 
studies of a variety of new drugs.  
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FIGURE LEGENDS 
 
Figure 1  : Transfection of HepaRG cells with the cationic lipophosphonates, lipophosphoramidates 
and glycine betaine lipids. 
The lipophosphonates EG316 (A) and GLB43 (B) and lipophosphoramidate KLN25 (C), BSV10 (D) 
and KLN47 (F) and the glycine betaine lipid MM18 (E) were used to transfect progenitor HepaRG 
cells. 105 adherent cells were transfected with 0.8 µg of pEGFPC3 vector and cationic lipids either 
used alone (charts of the left side) or combined with neutral the co-lipid DOPE or cholesterol (Chol) 
[charts of the right side] at different charge ratios (from 0.5 to 16: abscissa axis). GFP expression 
(histograms) and cell viability (lines) were detected by flow cytometry 48 h after transfection. 
Background fluorescence was determined for all liposome formulations using the non coding pc3 
DNA plasmid. Results of three independent experiments are expressed as percentages of GFP positive 
cells and cell viability compared to non transfected control cells (NT).  
 
Figure 2 : Transfection of progenitor and differentiated HepaRG cells by electroporation. 
The Microporator MP100 [NeonTM system from Invitrogen (Carlsbad, USA)] designed to deliver 
DNA into cells in suspension was used to transfect 0.5 µg of pEGFPC3 expression vector encoding 
the GFP reporter gene in 105 progenitor (A) and differentiated (B) HepaRG cells. GFP expression 
(histograms) and cell viability (lines) were detected by flow cytometry. Results of three independent 
experiments are expressed as percentages of GFP positive cells and cell viability compared to non 
transfected control cells (NT). Progenitor and differentiated HepaRG cells expressing GFP were 
visualized by fluorescence microscopy and phase contrast (photographs on the right side, white bar: 20 
µm). 
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Figure 3 : Transient enforced expression of the CYP2E1 in differentiated HepaRG cells 
Progenitor (Prog. cells) and differentiated HepaRG (Diff. cells) cells were electroporated (A) or 
transfected with the BSV10/DOPE and KLN47 liposomes (C) and the GFP or CYP2E1 expression 
vector (+ indicates the vector used). The expression levels of the CYP3A4, CYP2E1 and the GFP were 
analyzed by immunoblotting and Hsc70 was used as loading control. First lane of panel C: 
differentiated HepaRG electroporated (EP) with the CYP2E1 vector. In electroporated cells, the 
CYP2E1-specific enzymatic activities were measured using the chlorzoxazone as substrate followed 
by detection of the 6-hydroxychlorzoxazone metabolite by HPLC (B). Results of three independent 
experiments are expressed as the fold increase in CYP2E1-specific enzymatic activity compared to the 
basal activity (arbitrarily set as 1) in differentiated HepaRG cells transfected with the GFP vector (B).  
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